Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.06) per share and revenue of $7.41 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $11.04 on Thursday. The firm has a 50 day simple moving average of $10.81 and a two-hundred day simple moving average of $8.17. Entrada Therapeutics has a one year low of $4.93 and a one year high of $13.82. The company has a market cap of $421.95 million, a P/E ratio of -4.43 and a beta of -0.12.

Analyst Upgrades and Downgrades

TRDA has been the subject of several recent analyst reports. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday. Finally, Roth Mkm set a $13.00 price objective on shares of Entrada Therapeutics in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Entrada Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Insider Transactions at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 8,910 shares of Entrada Therapeutics stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $9.98, for a total transaction of $88,921.80. Following the sale, the chief financial officer directly owned 110,026 shares in the company, valued at $1,098,059.48. This trade represents a 7.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.11% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the business. Millennium Management LLC boosted its position in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares in the last quarter. Citadel Advisors LLC lifted its stake in Entrada Therapeutics by 234.5% in the third quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after buying an additional 235,384 shares during the period. Qube Research & Technologies Ltd boosted its holdings in shares of Entrada Therapeutics by 115.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after buying an additional 154,143 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Entrada Therapeutics by 4,767.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock worth $860,000 after buying an additional 145,167 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Entrada Therapeutics during the 3rd quarter worth approximately $753,000. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.